SEGMENT REPORTING (Tables)

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Reconciliation of other significant reconciling items from segments to consolidated

Summarized financial information concerning the Company's reportable segments is shown in the following tables (in thousands):

Three Months Ended March 31, 2020	Core Companion Animal			Other Vaccines and Pharmaceuticals			Total
Total revenue	$	27,306		$	3,348		$	30,654
Operating loss	(4,180		)	(438		)	(4,618		)
Loss before income taxes	(6,379		)	(438		)	(6,817		)
Capital expenditures	128			82			210
Depreciation and amortization	1,042			332			1,374

Three Months Ended March 31, 2019	Core Companion Animal			Other Vaccines and Pharmaceuticals			Total
Total revenue	$	24,716		$	4,795		$	29,511
Operating loss	(51		)	(24		)	(75		)
Loss before income taxes	(35		)	(24		)	(59		)
Capital expenditures	44			190			234
Depreciation and amortization	947			318			1,265

Schedule of revenue from external customers and long-lived assets, by geographical areas

Asset information by reportable segment as of March 31, 2020 is as follows (in thousands):

As of March 31, 2020	Core Companion Animal		Other Vaccines and Pharmaceuticals		Total
Investments in unconsolidated affiliates	$	7,295	$	—	$	7,295
Total assets	331,932		19,049		350,981
Net assets	255,237		15,401		270,638

Asset information by reportable segment as of December 31, 2019 is as follows (in thousands):

As of December 31, 2019	Core Companion Animal		Other Vaccines and Pharmaceuticals		Total
Investments in unconsolidated affiliates	$	7,424	$	—	$	7,424
Total assets	223,980		20,444		244,424
Net assets	137,072		17,292		154,364